← Patent-cliff monitor small molecule XALKORI CRIZOTINIB
Loss of exclusivity November 2029 latest FDA-listed patent expiry
Company PF PRISM CV
Drug detail Brand name XALKORI Active ingredient CRIZOTINIB Strength 200MG Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval August 2011 Marketing status RX
Listed patents Patent Expires Type 8217057 November 2029 substance, product 7858643 October 2029 substance, product 7825137 May 2027 use U-3057
Regulatory exclusivity Code Expires ODE-407 July 2029 ODE-328 January 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.